Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10126053 | 0.97 | NPC1 (0.46) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10125887 | 0.88 | SMN1; SMN2 (0.44) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10126054 | 0.85 | KDM4E (0.40) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL13621038 | 0.83 | NPC1 (0.49) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10125862 | 0.83 | SMN1; SMN2 (0.55) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10125891 | 0.81 | KDM4E (0.45) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10125879 | 0.80 | SMN1; SMN2 (0.46) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10126039 | 0.80 | SMN1; SMN2 (0.51) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10125882 | 0.80 | SMN1; SMN2 (0.48) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 | |
| SCHEMBL10125885 | 0.80 | NPC1 (0.48) | NPC1RAB9AKDM4ESMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119259-B2 | Quinoxaline derivative, and light-emitting element and electronic device using the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119259-B2 | Quinoxaline derivative, and light-emitting element and electronic device using the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20090140642-A1 | Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-06-04 | — | — | US | disclosed |
| US-20090140642-A1 | Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090140642-A1 | Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same | NDUFA11, NDUFA9, NDUFA12 | NPC1 4763/4885RAB9A 1141/4885KDM4E 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.